Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...
Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage ...
In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...
After weeks of disruption to scientific federal grants, the National Institutes of Health has fallen behind in funding ...
In statements and interviews with The Crimson, nine life sciences researchers at Harvard — from the Harvard School of Public ...
Women whose breast cancers need estrogen to grow are often treated for five or more years with medications to lower estrogen ...
A torrent of Trump administration policies is alarming scientists who fear the current climate is weakening researchers’ ...
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.
Private investment in pharmaceutical research can't replace the NIH. Both public investment and the private sector are needed ...
R&D expenditures $188.5 million in fiscal year 2023 contributing research-based advancements, generating jobs and infrastructure for Nevada. The University is home to dozens of state-of-the-art ...
The recently re-elected President of the USA's decision to withdraw the USA from WHO is highly regrettable on multiple levels, and hopefully will be quickly reconsidered.1,2 But if it holds, it ...